Entocort EC, a new ORAL form of budesonide for Crohn's disease

November 2001

AstraZeneca will soon introduce Entocort EC, a new ORAL form of budesonide for Crohn's disease.

This new steroid is approved for acute flare-ups that involve the ileum and/or ascending colon.

Entocort EC releases budesonide in the small intestine and colon to decrease inflammation.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote